✦ LIBER ✦

9166 Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations

✍ Scribed by De Greve, J.; Teugels, E.; Geers, C.; DeMey, J.; in 'tveld, P.; Decoster, L.; Taton, M.; Shahidi, M.; Galdermans, D.; Schallier, D.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical activity of afatinib (BIBW 2992

✍ De Grève, J.; Teugels, E.; Geers, C.; Decoster, L.; Galdermans, D.; De Mey, J.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 618 KB

573 POSTER Phase I study of BIBW2992, an

✍ R. Plummer; L. Vidal; L. Li; H. Shaw; R. Perrett; M. Shahidi; A. Amelsberg; G. T 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 67 KB

EGFR inhibitors in non-small cell lung c

✍ James F. Spicer; Sarah M. Rudman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 239 KB

567 POSTER Efficacy of BIBW 2992, an irr

✍ F. Solca; A. Baum; F. Himmelsbach; A. Amelsberg; G. Adolf 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB

143 Growth response of human colorectal

✍ S. Khelwatty; S. Essapen; A.M. Seddon; H. Modjtahedi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

118 Responses of human pancreatic tumour

✍ N. Ioannou; A. Dalgleish; A.M. Seddon; D. Mackintosh; U. Guertler; F. Solca; H. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB